Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowering Treatment in Chinese Participants

NCT03768427 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT03768427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03768427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowering Treatment in Chinese Participants
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
May 27, 2019
Completion date
April 1, 2021
Enrollment
454 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia